(Q37871513)

24 August 2017

1 reference

title

Long-term management issues in restless legs syndrome (English)

1 reference

24 August 2017

Long‐term management issues in restless legs syndrome (English)

1 reference

1 December 2024

Sudhansu Chokroverty

1 reference

24 August 2017

language of work or name

English

0 references

publication date

29 April 2011

1 reference

full work available at URL

24 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.23652

1 reference

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.23652/fullpdf

1 December 2024

1 reference

1 December 2024

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1378-1385

1 reference

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group

24 August 2017

cites work

1 reference

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

21 January 2018

1 reference

Restless legs syndrome prevalence and impact: REST general population study

21 January 2018

1 reference

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study

21 January 2018

1 reference

Efficacy and safety of pramipexole in restless legs syndrome

21 January 2018

1 reference

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

21 January 2018

1 reference

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

21 January 2018

1 reference

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial

21 January 2018

1 reference

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States

21 January 2018

1 reference

Long-term treatment of restless legs syndrome with dopamine agonists

21 January 2018

1 reference

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

21 January 2018

1 reference

Long-term treatment with pramipexole in restless legs syndrome

21 January 2018

1 reference

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

21 January 2018

1 reference

Restless legs syndrome: clinical experience with long-term treatment

21 January 2018

1 reference

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

21 January 2018

1 reference

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

21 January 2018

1 reference

EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep

21 January 2018

1 reference

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study

21 January 2018

1 reference

Using difficulty resuming sleep to define nocturnal awakenings

21 January 2018

1 reference

Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome

21 January 2018

1 reference

EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls

21 January 2018

1 reference

Sleep duration and mortality: a systematic review and meta-analysis

21 January 2018

1 reference

Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation

21 January 2018

1 reference

Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome.

21 January 2018

1 reference

Associations between sleep loss and increased risk of obesity and diabetes

21 January 2018

1 reference

Sleep and the epidemic of obesity in children and adults

21 January 2018

1 reference

The metabolic consequences of sleep deprivation

21 January 2018

1 reference

Sleep and metabolism: bringing pieces of the jigsaw together

21 January 2018

1 reference

Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study

21 January 2018

1 reference

Impact of sleep and sleep loss on glucose homeostasis and appetite regulation.

21 January 2018

1 reference

Restless legs syndrome augmentation associated with tramadol

21 January 2018

1 reference

Restless legs syndrome augmentation and pramipexole treatment

21 January 2018

1 reference

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

21 January 2018

1 reference

Effective cabergoline treatment in idiopathic restless legs syndrome

21 January 2018

1 reference

Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study

21 January 2018

1 reference

Rotigotine transdermal patch: in restless legs syndrome

21 January 2018

1 reference

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

21 January 2018

1 reference

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

21 January 2018

1 reference

The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels

21 January 2018

1 reference

Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

21 January 2018

1 reference

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

Pergolide-associated ‘sleep attacks’ in a patient with restless legs syndrome

21 January 2018

1 reference

Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome

21 January 2018

1 reference

The two faces of Eve: dopamine's modulation of wakefulness and sleep

21 January 2018

1 reference

Restless legs syndrome: Understanding its consequences and the need for better treatment

21 January 2018

1 reference

Impulsive and compulsive behaviors in Parkinson's disease

21 January 2018

1 reference

Drug addiction: the neurobiology of disrupted self-control

21 January 2018

1 reference

At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists.

21 January 2018

1 reference

Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome

21 January 2018

1 reference

Sleep-related smoking syndrome

21 January 2018

1 reference

Compulsive habits in restless legs syndrome patients under dopaminergic treatment

21 January 2018

1 reference

Dopamine dysregulation syndrome in a patient with restless legs syndrome.

21 January 2018

1 reference

Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient

21 January 2018

1 reference

Dopamine agonist withdrawal syndrome in Parkinson disease

21 January 2018

1 reference

Long-term follow-up on restless legs syndrome patients treated with opioids

21 January 2018

1 reference

Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation

21 January 2018

1 reference

VIM deep brain stimulation does not improve pre-existing restless legs syndrome in patients with essential tremor

21 January 2018

1 reference

Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease

21 January 2018

1 reference

Peridural morphine administration in restless legs status

21 January 2018

1 reference

Augmentation of restless legs syndrome with long-term tramadol treatment

21 January 2018

1 reference

Treatment of restless legs syndrome with levodopa plus benserazide

21 January 2018

1 reference

Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)

1 December 2024

1 reference

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

1 December 2024

1 reference

Pramipexole in the treatment of restless legs syndrome: a follow-up study

1 December 2024

1 reference

Pramipexole in the management of restless legs syndrome: an extended study

1 December 2024

1 reference

Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo.

1 December 2024

1 reference

Pregabalin in restless legs syndrome with and without neuropathic pain

1 December 2024

1 reference

Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study.

1 December 2024

1 reference

The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study

1 December 2024

1 reference

Augmentation of the restless legs syndrome with carbidopa/levodopa.

1 December 2024

1 reference

Pramipexole in the management of restless legs syndrome: an extended study

1 December 2024

1 reference

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial

1 December 2024

1 reference

Pathological gambling associated with dopamine agonist use in restless legs syndrome

1 December 2024

1 reference

Predictors of impulsivity and reward seeking behavior with dopamine agonists

1 December 2024

1 reference

1 December 2024

Identifiers

DOI

10.1002/MDS.23652

1 reference

24 August 2017

1 reference